Pasithea Therapeutics Corp. Warrants - KTTAW STOCK NEWS

Welcome to our dedicated page for Pasithea Therapeutics Warrants news (Ticker: KTTAW), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics Warrants stock.

Pasithea Therapeutics Corp is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. Leveraging expertise in neuroscience, translational medicine, and drug development, the company's pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.

08/01/2023 07:59 AM

News

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function

Rhea-AI Summary

Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced a publication in the Proceedings of the National Academy of Sciences related to its PAS-003 drug discovery program targeting α5/β1 integrin for the treatment of amyotrophic lateral sclerosis (ALS). The study reveals increased integrin expression in ALS patient tissues, specificity of α5 integrin in ALS, and the efficacy of a monoclonal antibody against α5 integrin in improving survival and motor function in the SOD1G93A mouse model of ALS.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.33%

Tags

07/20/2023 08:43 AM

News

Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

Rhea-AI Summary

Pasithea Therapeutics Corp. announces a $4.0 million tender offer to repurchase up to 5.7 million shares of its common stock at $0.70 per share. The offer is expected to close in Q3 2023.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

25.9%

Tags

07/20/2023 08:40 AM

News

Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

25.9%

Tags

06/30/2023 09:28 AM

News

Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors

Rhea-AI Summary

Pasithea Therapeutics Corp. confirms that its Board of Directors has formed a special committee to evaluate an unsolicited proposal from Lucy Scientific Discovery Inc. to acquire all outstanding shares of Pasithea common stock. The committee is actively evaluating the proposal.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.08%

Tags

06/29/2023 08:29 AM

News

Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004

Rhea-AI Summary

Pasithea Therapeutics Corp. has completed manufacturing of GMP-compliant Phase 1 clinical supplies of its lead product candidate PAS-004, a next-generation macrocyclic MEK Inhibitor. The company expects to file an IND application with the FDA in the second half of 2023 and plans to initiate a Phase 1 clinical trial by the end of 2023.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

11.11%

Tags

06/06/2023 04:30 PM

News

Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.

Rhea-AI Summary

Pasithea Therapeutics Corp. has received an unsolicited proposal from Lucy Scientific Discovery Inc. to acquire all outstanding shares of Pasithea common stock. The proposal includes $0.60 in cash plus $0.25 worth of Lucy common stock per share. Pasithea's Board of Directors will review and evaluate the proposal to determine the best course of action.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.63%

Tags

06/01/2023 07:57 AM

News

Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

05/03/2023 08:26 AM

News

Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference

Rhea-AI Summary

Pasithea Therapeutics Corp. to participate in EF Hutton Global Conference

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.89%

Tags

03/02/2023 08:00 AM

News

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting

Rhea-AI Summary

Pasithea Therapeutics Corp. (KTTA) announced that Prof. Lawrence Steinman will deliver a keynote address at the AAAS Annual Meeting on March 4, 2023. Prof. Steinman's research linking the Epstein-Barr virus to multiple sclerosis (MS) was recognized as a runner-up for the 2022 Science Magazine Breakthrough of the Year.

The company's PAS-002 program aims to develop a DNA plasmid vaccine targeting GlialCAM, a protein implicated in MS, providing potential treatment avenues for this chronic autoimmune disease affecting 2.8 million worldwide.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.8%

Tags

02/23/2023 08:00 AM

News

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Rhea-AI Summary

Pasithea Therapeutics Corp. announced that Lawrence Steinman, Chairman, will deliver a significant lecture at the ACTRIMS Forum in San Diego on February 23, 2023. The event, themed “MS: Going Viral,” focuses on the role of the Epstein-Barr virus in Multiple Sclerosis (MS), which relates to the Company's PAS-002 drug discovery program. PAS-002 aims to create an engineered DNA plasmid vaccine targeting GlialCAM, a protein implicated in MS. MS affects 2.8 million people globally, with relapsing remitting MS being the most common type. Steinman's research was recognized as a runner-up for Science Magazine’s 2022 Breakthrough of the Year.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-5.66%

Tags

FAQ

What is the current stock price of Pasithea Therapeutics Warrants (KTTAW)?

The current stock price of Pasithea Therapeutics Warrants (KTTAW) is $0.0252 as of November 1, 2024.

What is Pasithea Therapeutics Corp focused on?

Pasithea Therapeutics Corp is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies.

What is included in Pasithea Therapeutics Corp's pipeline?

The company's pipeline includes treatments for Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.

What areas of expertise does Pasithea Therapeutics Corp leverage?

Pasithea Therapeutics Corp leverages expertise in neuroscience, translational medicine, and drug development.

Who can be contacted for corporate communications at Pasithea Therapeutics Corp?

For corporate communications, you can reach out to Patrick Gaynes at pgaynes@pasithea.com.

When is the initial safety, tolerability, and biomarker data expected to be reported?

The initial safety, tolerability, and biomarker data are expected to be reported in the second half of 2024.

When is the initial interim safety and PK data release on track for?

The initial interim safety and PK data release is on track for the third quarter of 2024.

What diseases does Pasithea Therapeutics Corp focus on?

Pasithea Therapeutics Corp focuses on treating central nervous system (CNS) disorders, RASopathies, and other diseases.

What is Pasithea Therapeutics Corp's primary area of research?

The company's primary area of research is in developing treatments for central nervous system (CNS) disorders.

What is the core mission of Pasithea Therapeutics Corp?

The core mission of Pasithea Therapeutics Corp is to advance the treatment options for patients with CNS disorders and other related conditions.

How does Pasithea Therapeutics Corp contribute to the field of medicine?

Pasithea Therapeutics Corp contributes by developing innovative therapies for challenging conditions like Neurofibromatosis Type 1, ALS, MS, and Schizophrenia.